MarginsXMarginsX
Home › Markets › Health Care › RLMD

Relmada Therapeutics Inc. (RLMD)

RLMD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.61
-14.25% on the day
Market cap
$385.2M
Small cap
Revenue
No annual revenue filed since the period ending 2013-08-31
Net income
No annual revenue filed since the period ending 2013-08-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerRLMD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001553643
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

No annual revenue filed since the period ending 2013-08-31.

Warning signs

Cash runway
1.3 months
$5.7M cash at September 30, 2026
Share count, 1 year
+45.5%
2025-11-10 to 2026-11-10 · +254.5% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$4.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$5.7M cash; operating cash flow -$13.0M a quarter.Report 2026-09-30
Shares outstanding106,694,846 (2026-11-10); 73,333,622 a year earlier; 30,099,203 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-01-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Houston, Texas, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $4.0M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$13.9M-$12.6M$5.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$12.9M-$9.6M$11.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$19.1M-$15.1M$9.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$19.9M-$14.6M$3.5MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2025
2025-09-30
Not filed-$10.1M-$6.7M$1.4MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$9.9M-$6.4M$1.4MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$17.6M-$18.1M$1.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$18.7M-$8.8M$3.9MNo debt tagsNeeds four quarters10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-3ASR2026-05-13
Latest annual report
ANNUAL REPORT
10-K2026-03-19
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-11-16
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 610 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.9%
1 month+25.3%
3 months-11.4%
Year to date-12.8%
1 year+8.5%
From 52-week high-46.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CRMDCorMedix Inc.$4.82+3.43%$383.4M
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
PEPGPepGen Inc.$4.19-3.90%$395.0M
PRTAProthena Corporation plc$7.97-2.33%$409.3M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier